{"url_path":"/sec/inti/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","accession_number":"0001493152-26-023622","cik":"0001042418","ticker":"INTI","issuer_name":"Inhibitor Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","primary_entity_key":"0001042418","primary_entity_name":"Inhibitor Therapeutics, Inc."},"word_count":557,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0001042418\n\n0001042418\n\n2026-01-01\n2026-03-31\n\n0001042418\n\n2026-05-15\n\n0001042418\n\n2026-03-31\n\n0001042418\n\n2025-12-31\n\n0001042418\n\nus-gaap:SeriesAPreferredStockMember\n\n2026-03-31\n\n0001042418\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-12-31\n\n0001042418\n\nINTI:SeriesBConvertiblePreferredStockMember\n\n2026-03-31\n\n0001042418\n\nINTI:SeriesBConvertiblePreferredStockMember\n\n2025-12-31\n\n0001042418\n\nINTI:UndesignatedPreferredStockMember\n\n2026-03-31\n\n0001042418\n\nINTI:UndesignatedPreferredStockMember\n\n2025-12-31\n\n0001042418\n\n2025-01-01\n2025-03-31\n\n0001042418\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001042418\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001042418\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001042418\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001042418\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001042418\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001042418\n\n2024-12-31\n\n0001042418\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001042418\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001042418\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001042418\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001042418\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001042418\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001042418\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001042418\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001042418\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001042418\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001042418\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001042418\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001042418\n\n2025-03-31\n\n0001042418\n\n2026-02-19\n2026-02-19\n\n0001042418\n\nus-gaap:RoyaltyMember\nINTI:MaynePharmaVenturesPtyLtdMember\n\n2026-03-31\n\n0001042418\n\nus-gaap:RoyaltyMember\n\n2026-03-31\n\n0001042418\n\nus-gaap:RoyaltyMember\n\n2025-12-31\n\n0001042418\n\nINTI:AviorMember\n\n2026-01-01\n2026-03-31\n\n0001042418\n\nINTI:AviorMember\n\n2025-01-01\n2025-03-31\n\n0001042418\n\nus-gaap:InvestorMember\nINTI:SecuritiesPurchaseAgreementMember\n\n2026-02-19\n2026-02-19\n\n0001042418\n\nINTI:SecuritiesPurchaseAgreementMember\n\n2026-02-19\n\n0001042418\n\nINTI:SecuritiesPurchaseAgreementMember\n\n2026-02-19\n2026-02-19\n\n0001042418\n\nINTI:SecuritiesPurchaseAgreementMember\n\n2026-03-30\n\n0001042418\n\nINTI:EquityIncentivePlanMember\n\n2026-01-01\n2026-03-31\n\n0001042418\n\nINTI:EquityIncentivePlanMember\n\n2025-01-01\n2025-03-31\n\n0001042418\n\nINTI:EquityIncentivePlanMember\n\n2026-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nINTI:Segment\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n**(Mark\nOne)**\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from _______________to _______________**\n\n \n\n**Commission\nfile number 001-13467**\n\n \n\n**Inhibitor\nTherapeutics, Inc.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Delaware**\n \n**30-0793665**\n\n**(State\nor other jurisdiction of**\n\n**incorporation\nor organization)**\n\n \n\n**(I.R.S.\nEmployer**\n\n**Identification\nNo.)**\n\n \n \n \n\n**3014\nW. Palmira Avenue Suite 302**\n\n**Tampa,\nFL**\n\n \n**33629-7264**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n \n\n**Registrant’s\ntelephone number (including area code):**\n\n**813-864-2562**\n\n \n\n**Not\nApplicable**\n\n**(Former\nname, former address and former fiscal year, if changed since last report)**\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting\ncompany. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer\n☐\n \nAccelerated\nfiler\n☐\n\n \n \n \n \n \n\nNon-accelerated\nfiler\n☒\n \nSmaller\nreporting company\n☒\n\n \n \n \n \n \n\n \n \n \nEmerging\ngrowth company\n☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 15, 2026, there were 172,573,545 shares of company common stock issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Inhibitor\nTherapeutics, Inc.**\n\n**Quarterly\nReport on Form 10-Q**\n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \n**Page**\n\n \n \n \n\n**Part\nI. Financial Information**"}